866207-69-4

Usage

Uses

Used in Organic Synthesis:
(E)-Ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate is used as a reagent and intermediate in organic synthesis for its ability to facilitate the creation of complex molecular structures. Its unique properties make it a valuable component in the synthesis of a wide range of compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (E)-ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate is used as a key intermediate in the development of new drugs. Its incorporation into drug molecules can enhance their efficacy and selectivity, contributing to the advancement of medicinal chemistry.
Used in Agrochemicals:
(E)-Ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate is also utilized in the agrochemical sector, where it serves as a building block for the creation of various agrochemical products. Its role in this industry is crucial for the development of effective and targeted solutions for agricultural needs.
Used in Materials Science:
Due to its unique properties, (E)-ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate holds potential applications in the field of materials science. It can be used to develop new materials with specific characteristics, such as improved strength, durability, or chemical resistance.
Safety Precautions:
Given its potential toxicity, (E)-ethyl 3-(4-(trifluoromethoxy)phenyl)acrylate should be handled with care in both laboratory and industrial settings. Proper safety measures, including the use of personal protective equipment and adherence to safety protocols, are essential to minimize risks associated with its use.

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 659-28-9 p-trifluoromethoxybenzaldehyde 
• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 31930-36-6 ethyl (Z)-3-iodopropenoate 
• 103962-05-6 1-iodo-4-(trifluoromethoxy)benzene 
• 140-88-5 ethyl acrylate 

Downstream Products

• 199679-35-1 3-(4-trifluoromethoxyphenyl)acrylic acid 
• 1374855-77-2 (E)-N-(2-(4-cyclopropyl-4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-31-1 (E)-N-(2-(4-(N,N-dimethylsulfamoylamino)piperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-19-5 (E)-N-(4-methyl-2-(4-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl) quinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-18-4 (E)-N-(4-methyl-2-(4-(2-oxoimidazolidin-1-yl)piperidin-1-yl)quinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-16-2 (E)-N-(4-methyl-2-(4-(2-oxooxazolidin-3-yl)piperidin-1-yl)quinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-15-1 (E)-N-(2-(4-(2,5-dioxopyrrolidin-1-yl)piperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374855-74-9 (E)-N-(2-(4-hydroxypiperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-10-6 (E)-N-(4-methyl-2-(4-(2-oxopyrrolidin-1-yl)piperidin-1-yl)quinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-09-3 (E)-N-(4-methyl-2-(2-oxo-1,4'-bipiperidin-1'-yl)quinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-08-2 (E)-N-(4-methyl-2-(4-(3-oxomorpholino)piperidin-1-yl)quinazolin-6-yl)-3-(4 (trifluoromethoxy)phenyl)acrylamide 
• 1374856-28-6 (E)-N-(2-(4-(2-methoxyacetamido)piperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 1374856-27-5 (E)-N-(2-(4-(2-hydroxyacetamido)piperidin-1-yl)-4-methylquinazolin-6-yl)-3-(4-(trifluoromethoxy)phenyl)acrylamide 
• 183800-94-4 trans-4-(trifluoromethoxy)cinnamaldehyde 

Relevant academic research and scientific papers

Bimetallic nano alloy architecture on a special polymer: Ni or Cu merged with Pd for the promotion of the Mizoroki–Heck reaction and the Suzuki–Miyaura coupling

Abstract: Novel Ni-Pd and Cu-Pd bimetallic nano alloys was designed and heterogenized on the highly robust ABPBI [poly(2,5-benzimidazole)] polymer in high yields using NaBH4 as reducing agent. These were versatile ligand free catalysts for the Mizoroki–Heck reaction and Suzuki–Miyaura coupling. The bimetallic Ni-Pd-ABPBI catalyst for the Mizoroki–Heck reaction of 4-iodo anisole could be recycled 5 times with high yields. Aryl bromides could also be activated for the Mizoroki–Heck reaction using Cu-Pd-ABPBI NP catalysts, with moderate yields. Graphic abstract: Synopsis Novel bimetallic Ni-Pd and Cu-Pd nano alloys, heterogenized on the robust ABPBI [poly(2,5-benzimidazole)] polymer using NaBH4 as reducing agent, is described. These were versatile ligand free, noble metal conservative catalysts, for the Mizoroki–Heck reaction and the Suzuki–Miyaura coupling. Aryl bromides were activated for the Mizoroki–Heck reaction using the Cu-Pd-ABPBI catalyst.[Figure not available: see fulltext.]

Larvicidal activity and in silico studies of cinnamic acid derivatives against Aedes aegypti (Diptera: Culicidae)

Cinnamic acid derivatives (CAD's) represent a great alternative in the search for insecticides against Aedes aegypti mosquitoes since they have antimicrobial and insecticide properties. Ae. aegypti is responsible for transmitting Dengue, Chikungunya, and Zika viruses, among other arboviruses associated with morbimortality, especially in developing countries. In view of this, in vitro analyses of n-substituted cinnamic acids and esters were performed upon 4th instar larvae (L4) of Ae. aegypti, as well as, molecular docking studies to propose a potential biological target towards this mosquitoes species. The larvicide assays proved that n-substituted ethyl cinnamates showed a more pronounced activity than their corresponding acids, in which p-chlorocinnamate (3j) presented a LC50 value of 8.3 μg/mL. Thusly, external morphologic alterations (rigid and elongated body, curved bowel, and translucent or darkened anal papillae) of mosquitoes’ group exposed to compound 3j, were observed by microscopy. In addition, an analytical method was developed for the quantification of the most promising analog by using high-performance liquid chromatography with UV detection (HPLC-UV). Molecular docking studies suggested that the larvicide action is associated with inhibition of acetylcholinesterase (AChE) enzyme. Therefore, expanding the larvicidal study with the cinnamic acid derivatives against the vector Ae. aegypti is important for finding search for more effective larvicides and with lower toxicity, since they have already shown good larvicidal properties against Ae. aegypti.

Iron-Catalyzed Cross-Coupling of Bis-(aryl)manganese Nucleophiles with Alkenyl Halides: Optimization and mechanistic investigations

Various substituted bis-(aryl)manganese species were prepared from aryl bromides by one-pot insertion of magnesium turnings in the presence of LiCl and in situ trans-metalation with MnCl2 in THF at ?5 ?C within 2 h. These bis-(aryl)manganese reagents undergo smooth iron-catalyzed cross-couplings using 10 mol% Fe(acac)3 with various functionalized alkenyl iodides and bromides in 1 h at 25 ?C. The aryl-alkenyl cross-coupling reaction mechanism was thoroughly investigated through paramagnetic 1H-NMR, which identified the key role of tris-coordinated ate-iron(II) species in the catalytic process.

Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists: Part 2

Melanin concentrating hormone receptor 1 (MCHR1) antagonists have potential for the treatment of obesity and several CNS disorders. In the preceding article, we have described a novel series of quinazolines as MCHR1 antagonists and demonstrated in vivo proof of principle with an early lead. Herein we describe the detailed SAR and SPR studies to identify an optimized lead candidate having good efficacy in a sub-chronic DIO model with a good cardiovascular safety window.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

Synthesis and antifungal activities of R-102557 and related dioxane- triazole derivatives

Novel triazole compounds with a dioxane ring were synthesized. Condensation of the diol precursor 10 with various aromatic aldehydes 11 - 13 under acidic conditions afforded a series of dioxane-triazole compounds 14 - 16. The antifungal activities of the compounds 14 - 16 were evaluated in vivo in mice infection models against Candida and Aspergillus species. High activities were seen for the derivatives with one or two double bond(s) and an aromatic ring substituted with an electron-withdrawing group in the side chain. Among the derivatives, R-102557 (16R: Ar=4-(2,2,3,3- tetrafluoropropoxy)phenyl) showed excellent in vivo activities against Candida, Aspergillus and Cryptococcus species. It also showed high tolerance in a preliminary toxicity study in rats.